Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY - FEDBIZOPPS ISSUE OF DECEMBER 25, 2016 FBO #5511
SOLICITATION NOTICE

A -- Evaluation of Single Dose Protection Afforded by the Prophylactic HPV Vaccines

Notice Date
12/23/2016
 
Notice Type
Presolicitation
 
NAICS
541712 — Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
 
Contracting Office
Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
 
ZIP Code
20852
 
Solicitation Number
N01CP71015-82
 
Archive Date
1/24/2017
 
Point of Contact
Charles Park, Phone: 240-276-5896, Jill Johnson, Phone: 240-276-5395
 
E-Mail Address
charles.park@nih.gov, jill.johnson2@nih.gov
(charles.park@nih.gov, jill.johnson2@nih.gov)
 
Small Business Set-Aside
N/A
 
Description
THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR PROPOSAL. A SOLICITATION WILL BE ISSUED ON A LATER DATE. The National Cancer Institute (NCI), National Institutes of Health (NIH) is seeking to support a prospective clinical trial aimed at evaluating the non-inferiority of 1 versus 2 doses of the HPV vaccines. The contract will also permit an additional extension to the follow-up of women in NCI's ongoing Costa Rica Vaccine Trial (CVT), which initially followed women for 10 years and will now extend that follow-up out to 15 years among a subset of participants. CVT showed similar HPV vaccine efficacy over four years among women who received one, two and three doses of the HPV16/18 vaccine, and stable antibody responses have been observed throughout the seven years of follow-up accrued to date in CVT, following up on these discoveries and further documenting the protection afforded by fewer doses could result in a monumental, global public health breakthrough. Thus, this new trial that will directly evaluate the protection afforded by single-dose and two-dose regimens of the prophylactic HPV vaccines. Continuation of the current cohort will document durability of antibody titers among women who received fewer doses. The services will be acquired through full and open competitive procedures under NAICS 541712. It is anticipated that one (1) cost reimbursement type contract will be awarded with a twelve (12) month base period and five 1-year options. The base period of performance will begin in 2017. The RFP will be available electronically at a later date and may be accessed through the FedBizOpps at www.fbo.gov. WE ENCOURAGE ALL RESPONSIBLE SOURCES, PARTICULARLY SMALL BUSINESSES, TO SUBMIT A PROPOSAL WHICH WILL BE CONSIDERED BY THE AGENCY. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile or email transmissions will be accepted. IT IS THE OFFERORS' RESPONSIBILITY TO MONITOR THE ABOVE-MENTIONED SITE FOR THE RELEASE OF THE SOLICITATION AND ANY AMENDMENTS.
 
Web Link
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N01CP71015-82/listing.html)
 
Record
SN04359980-W 20161225/161223233132-117128c826eafbd4dd9df56950bbc863 (fbodaily.com)
 
Source
FedBizOpps Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.